As healthcare-associated infections continue to burden the medical system and grab headlines, Astellas and ClearPath Development are forming a vaccines company looking to help tackle the issue.
Astellas first joined forces with Immunomic Therapeutics in February, contributing $15 million up front for a vaccine against allergies caused by Japanese red cedar. Now, the duo is entering another partnership, with Astellas handing over $300 million up front for the exclusive license to Immunomic's LAMP-vax technology to develop vaccines for human allergies.
Japan's Astellas Pharma has splashed out $300 million to U.S.-based Immunomic Therapeutics for its LAMP-vax platform to treat or prevent allergic diseases, gaining exclusive global development and commercialization rights, according to a press release.
Japanese drugmaker Astellas is expanding its pipeline of analgesics, signing a deal worth up to $515 million for the rights to a new treatment for nerve pain.
Astellas is partnering with both USA Rugby and the Australia Rugby Union for a new prostate cancer campaign. Though it's an unbranded push, the "Pass4Prostate" promotion fits right in with Astellas' stepped-up marketing of Xtandi, the prostate cancer med now approved for previously untreated patients.
Astellas and Medivation haven't been marketing Xtandi much for the pre-chemotherapy indication in prostate cancer it won last fall. Begun two months ago, the direct-to-consumer efforts--mostly in print--has appeared in journals such as Patient Resourc e; it also includes some direct relationship marketing.
Japanese drugmaker Astellas is teaming up with a Swiss biotech to launch a joint venture focused on autoimmune disease, promising up to $760 million with an option to buy the new company outright.
Astellas and Medivation may have disappointed analysts with their first-quarter Xtandi sales. But recent script numbers suggest the disappointment may be short-lived--and that the prostate cancer pill may be gaining ground on its head-to-head rival, Johnson & Johnson's Zytiga.
Japanese pharma giant Astellas is entering the booming field of immuno-oncology, pairing up with Cambridge, MA's Potenza Therapeutics to work on a wide variety of treatments that use the body's natural defenses to combat cancer.
Japan's Astellas Pharma and U.K.-based biotech Potenza Therapeutics announced a R&D; effort into immuno-oncology therapies centered on checkpoint pathways, co-stimulatory signals and regulatory T cells that could lead to a buyout.